Ovarian Cancer Clinical Trials in Palo Alto, California

6 studies are recruiting for ovarian cancer in Palo Alto, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

   This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06646627 on ClinicalTrials.gov

2. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Stanford University, Palo Alto, California

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

3. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

   Stage

   Phase 1

   Ages

   15 and older

   Site

   Stanford, Palo Alto, California

   Locations

   22 in total

   Run by

   Xencor, Inc.

   See if you can join NCT06276491 on ClinicalTrials.gov

4. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University School of Medicine, Palo Alto, California

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

5. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

   This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   150, Palo Alto, California

   Locations

   49 in total

   Run by

   Corcept Therapeutics

   See if you can join NCT06906341 on ClinicalTrials.gov

6. Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

   This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-g…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Palo Alto Medical Foundation, Palo Alto, California

   Locations

   208 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06819007 on ClinicalTrials.gov